CLOVER HEALTH INVESTMENTS, CORP. /DE — Form 8-K

Clover Health released a supplemental shareholder Q&A (August 20, 2026) addressing Q2 2026 results and business outlook. Key disclosures: CA-managed members in year 3 generate ~$155 PMPM more gross profit than year 1; CA-managed cohorts show ~18% better MCR in year 3; chronic kidney disease members receiving CA care diagnosed 18 months earlier with 72% slower kidney function decline; ~49% of membership in years 1–2, still early in maturation curve; company retains full underwriting risk; 31% market share in New Jersey individual non-SNP MA; 4.5 Star ratings confirmed for 2027; Counterpart Health (external CA offering) described as early-stage, not yet materially profitable; company expects operating leverage from AI deployment in back-office claims and member service. No specific dollar amounts, enrollment numbers, or financial targets disclosed; management reiterates no formal 2027 guidance.